Department of Medicine, Division of Endocrinology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Robert and Arlene Kogod Center on Aging, Rochester, MN, USA.
J Bone Miner Res. 2018 Apr;33(4):720-731. doi: 10.1002/jbmr.3351. Epub 2017 Dec 27.
There is a clinical need to identify new molecular targets for the treatment of osteoporosis, particularly those that simultaneously inhibit bone resorption while stimulating bone formation. We have previously shown in overexpression studies that retinoic acid receptor-related orphan receptor β (Rorβ) suppresses in vitro osteoblast differentiation. In addition, the expression of Rorβ is markedly increased in bone marrow-derived mesenchymal stromal cells with aging in both mice and humans. Here we establish a critical role for Rorβ in regulating bone metabolism using a combination of in vitro and in vivo studies. We used Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene editing to demonstrate that loss of Rorβ in osteoblasts enhances Wnt signaling, specifically through increased recruitment of β-catenin to T-cell factor/lymphoid enhancer factor (Tcf/Lef) DNA binding sites in the promoters of the Wnt target genes Tcf7 and Opg. This resulted in increased osteogenic gene expression and suppressed osteoclast formation through increased osteoprotegerin (OPG) secretion in Rorβ-deficient cells. Consistent with our in vitro data, genetic deletion of Rorβ in both female and male mice resulted in preserved bone mass and microarchitecture with advancing age due to increased bone formation with a concomitant decrease in resorption. The improved skeletal phenotype in the Rorβ mice was also associated with increased bone protein levels of TCF7 and OPG. These data demonstrate that loss of Rorβ has beneficial skeletal effects by increasing bone formation and decreasing bone resorption, at least in part through β-catenin-dependent activation of the Wnt pathway. Thus, inhibition of Rorβ represents a novel approach to potentially prevent or reverse osteoporosis. © 2017 American Society for Bone and Mineral Research.
临床上需要确定骨质疏松症的新分子靶点,特别是那些既能抑制骨吸收又能刺激骨形成的靶点。我们之前的过表达研究表明,维甲酸受体相关孤儿受体β(Rorβ)抑制体外成骨细胞分化。此外,在小鼠和人类中,随着年龄的增长,骨髓间充质基质细胞中 Rorβ 的表达明显增加。在这里,我们使用体外和体内研究相结合的方法,确立了 Rorβ 在调节骨代谢中的关键作用。我们使用规律成簇间隔短回文重复序列(CRISPR)/Cas9 基因编辑来证明成骨细胞中 Rorβ 的缺失增强了 Wnt 信号,特别是通过增加β-catenin募集到 Wnt 靶基因 Tcf7 和 Opg 启动子中的 Tcf/Lef DNA 结合位点。这导致成骨基因表达增加,破骨细胞形成减少,原因是 Rorβ 缺陷细胞中骨保护素(OPG)分泌增加。与我们的体外数据一致,雌性和雄性小鼠中 Rorβ 的基因缺失导致随着年龄的增长骨量和微结构得以保留,这是由于骨形成增加,同时吸收减少。Rorβ 小鼠的骨骼表型改善也与骨蛋白 TCF7 和 OPG 水平的增加有关。这些数据表明,Rorβ 的缺失通过增加骨形成和减少骨吸收对骨骼产生有益的影响,至少部分是通过 β-catenin 依赖性激活 Wnt 途径。因此,抑制 Rorβ 代表了一种预防或逆转骨质疏松症的新方法。